Those who cheered ivermectin as a Covid-19 treatment, like Marjorie Taylor Greene, are now making unsubstantiated claims ...
Intercept Pharmaceuticals has been gearing up for the potential launch of its nonalcoholic steatohepatitis (NASH) med, but now its wait looks a little longer. While the FDA was originally due to ...
(Reuters) -Intercept Pharmaceuticals Inc will resubmit its application for approval of its therapy for a chronic liver disease to the U.S. Food and Drug Administration, two years after the regulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results